City Therapeutics, Inc. Common Stock (CTY) FinancialsCTYCity Therapeutics, Inc. Common Stock

Evaluating the bottom line, City Therapeutics, Inc. maintains a gross margin of 66.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 17.73%, provide a clear picture of how effectively CTY converts its operational activities into shareholder value.

In the context of the broader market, CTY competes directly with industry leaders such as REPL and VOR. With a market capitalization of $1.13B, it holds a significant position in the sector. When comparing efficiency, CTY's gross margin of 66.02% stands against REPL's N/A and VOR's N/A. Such benchmarking helps identify whether City Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has a P/E ratio of 0.58 and a price-to-sales ratio of 72.89, which indicates it may be overvalued relative to its sales. The forward P/E is 0, suggesting no expected earnings growth in the near term.